Yonhap Infomax NewsCelltrion will acquire Eli Lilly’s New Jersey biopharmaceutical plant for 460 billion won ($335 million), investing at least 1.4 trillion won ($1.02 billion) to expand US production capacity and fully eliminate tariff risks, with operations set to begin in 2027 pending regulatory approval.
#YonhapInfomax #Celltrion #EliLilly #BiopharmaceuticalPlant #TariffRisk #InvestmentAmount #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=82977
#YonhapInfomax #Celltrion #EliLilly #BiopharmaceuticalPlant #TariffRisk #InvestmentAmount #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=82977
Celltrion Acquires Eli Lilly’s US Plant for 460 Billion Won—“Fully Eliminates Tariff Risk”
Celltrion will acquire Eli Lilly’s New Jersey biopharmaceutical plant for 460 billion won ($335 million), investing at least 1.4 trillion won ($1.02 billion) to expand US production capacity and fully eliminate tariff risks, with operations set to begin in 2027 pending regulatory approval.